Philips' Fetal-Maternal Monitors Designed with Clinicians and Patients in Mind

Royal Philips ElectronicsRoyal Philips Electronics (NYSE: PHG, AEX: PHI) today announced the release of its Avalon FM40 and FM50 fetal-maternal monitors. The Avalon FM40 and FM50 are the newest additions to the Avalon family of fetal-maternal products, which includes the Avalon Cordless Transducer System (CTS) and the Avalon FM20 and FM30 fetal-maternal monitors.

These innovative monitors can feature a one-of-a-kind external display with touch-screen capability that customers can choose as an option in addition to the monitor's built-in, 6.5 inch color, touch-screen display. This larger external display, which comes in various sizes, can be mounted across the room, on a furniture cart in the labor and delivery room, or other convenient locations. This makes the monitors easier for clinicians to use because it allows them to interact with the fetal monitor even when they are not at the patient's bedside.

The new monitors were specifically designed with clinicians and patients in mind. "We constantly seek feedback from our customers, who told us they needed new, advanced features in a fetal monitor with the ability to maximize their investment by utilizing existing cart furniture," said David Russell, vice president of global marketing for Patient Monitoring, Philips Healthcare. "By creating the Avalon FM40 and FM50 with a familiar footprint, combined with new, cutting-edge technology and the patient-centric design of the Avalon family, we are fully equipped to meet this need."

Philips understands that patient comfort is extremely important, so the Avalon transducers are constructed with a softer material which adds to the comfort of the mother during antepartum and labor and delivery monitoring. The large, external display allows the family of the patient to become more involved in the birth experience since they can more easily view what is going on at all times; and for obstetricians and nurse/midwives to be able to view pertinent patient information at a distance. The ability to interface the FM40 and FM50 with the Avalon Cordless Transducer System (CTS) allows the mother to be mobile while she and her baby are being continuously monitored.

The Philips Avalon FM40 and FM50 provide clinicians with advanced, intuitive technologies to care for expectant mothers and their babies. As with the rest of the Avalon fetal-maternal monitoring family, vital patient data is continuously captured by the built-in data buffer system with the added capability of selective data printout, which reduces the risk of data loss. The monitors also feature "smart" transducers with universal plug and play connectors to enhance ease of use. Replacement parts, such as the cables, can be exchanged easily without having to replace an entire unit, reducing the cost of service.

The Philips Avalon FM40 antepartum monitor provides an extensive set of external monitoring capabilities, such as external monitoring of uterine activity, up to three fetal heart rates and fetal movement profile (FMP) via ultrasound. The Avalon FM50 intrapartum monitor includes the external monitoring capabilities of the FM40 and internal fetal measurements including fetal heart rate via direct fetal ECG and intrauterine pressure. Both monitors provide monitoring of maternal blood pressure, SpO2, maternal ECG and maternal heart rate. Both fetal and maternal ECG waves can be displayed on the screen. These new high-end intrapartum and antepartum monitors easily integrate with Philips' obstetrical information system, OB TraceVue, as well as other information systems.

"Fetal monitoring is the standard of care in most modern labor and delivery care settings the world over, but with increasing multiple births, monitoring of twins and triplets is now a required functionality," said Russell. "Like the Avalon FM20 and FM30, the FM40 and FM50 can monitor up to three babies and the mother simultaneously while providing cross channel verification to discriminate between maternal and separate fetal heart rates. Philips is the only provider of non-invasive triplet monitoring in one device."

Russell continued, "The newest addition to the Avalon family further enhances care-givers' ability to provide quality care in a more patient-focused environment by providing advanced monitoring that is extremely intuitive. The capabilities of the Philips fetal-maternal monitoring portfolio help healthcare facilities to differentiate their services and provide expectant mothers with high quality obstetrical care."

About Royal Philips Electronics
Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX: PHI) is a global leader in healthcare, lighting and consumer lifestyle, delivering people-centric, innovative products, services and solutions through the brand promise of "sense and simplicity". Headquartered in the Netherlands, Philips employs approximately 123,800 employees in more than 60 countries worldwide. With sales of EUR 27 billion in 2007, the company is a market leader in medical diagnostic imaging and patient monitoring systems, energy efficient lighting solutions, as well as lifestyle solutions for personal wellbeing. News from Philips is located at www.philips.com/newscenter.

Most Popular Now

ChatGPT Shows 'Impressive' Acc…

A new study led by investigators from Mass General Brigham has found that ChatGPT was about 72 percent accurate in overall clinical decision making, from coming up with possible diagnoses...

WiFi SPARK's Healthcare Business Re…

Leading WiFi provider WiFi SPARK is rebranding its healthcare arm as SPARK Technology Services Limited. The new identity marks the completion of the integration of the former Hospedia bedside unit...

Online AI-Based Test for Parkinson'…

An artificial intelligence (AI) tool developed by researchers at the University of Rochester can help people with Parkinson's disease remotely assess the severity of their symptoms within minutes. A study...

ChatGPT is Debunking Myths on Social Med…

ChatGPT could help to increase vaccine uptake by debunking myths around jab safety, say the authors of a study published in the peer-reviewed journal Human Vaccines and Immunotherapeutics. The researchers asked...

AI Performs Comparably to Human Readers …

Using a standardized assessment, researchers in the UK compared the performance of a commercially available artificial intelligence (AI) algorithm with human readers of screening mammograms. Results of their findings were...

Siemens Healthineers Expands Production …

Siemens Healthineers is expanding its site in Rudolstadt, Germany. By mid 2024, a new manufacturing building will be built on the site. The new manufacturing plant will produce electron accelerators...

More Cases of Breast Cancer Detected wit…

One radiologist supported by AI detected more cases of breast cancer in screening mammography than two radiologists working together, reports the ScreenTrustCAD study from Karolinska Institutet in The Lancet Digital...

ChatGPT Performs as Well as Doctors for …

The artificial intelligence chatbot ChatGPT performed as well as a trained doctor in suggesting likely diagnoses for patients being assessed in emergency medicine departments, in a pilot study to be...

Smartphone Technology Expected to Advanc…

Since the 1980s, we have known that neurological soft signs (NSS) can distinguish people with schizophrenia from psychiatrically healthy individuals. NSS are subtle neurological impairments that principally manifest as decreased...

AI may Outperform Most Humans at Creativ…

Large language model (LLM) artificial intelligence (AI) chatbots may be able to outperform the average human at a creative thinking task where the participant devises alternative uses for everyday objects...

MEDICA 2023 + COMPAMED 2023: "Where…

13 - 16 November 2023, Düsseldorf, Germany. The medical technology market is in worldwide motion and the signs ahead of MEDICA 2023 and COMPAMED 2023 in Düsseldorf as the internationally leading...

AI and Machine Learning can Successfully…

Artificial intelligence (AI) and machine learning (ML) can effectively detect and diagnose Polycystic Ovary Syndrome (PCOS), which is the most common hormone disorder among women, typically between ages 15 and...